Get started
Author

Lisa Argnani

Observed names: ARGNANI, LISA, Argnani L, Argnani, Lisa, L Argnani, L. Argnani, Lisa ARGNANI, Pier Luigi Zinzani
Observed institutions: University of Ferrara, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Azienda Ospedaliero Universitaria San Giovanni Battista, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Istituto di Ematologia di Bologna, Azienda Ospedaliero Universitaria Maggiore della Carita, Fondazione Intergruppo Italiano Linfomi Onlus, Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, University of Bologna
ORCID: 0000-0003-4225-4626
Observed ORCID: 0000-0003-4225-4626
OpenAlex ID: A5044832096
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
2009 · P.L. Zinzani, F. Venturini, et al. · Annals of Oncology · 193
PDF
Interim Positron Emission Tomography Response–Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study
2016 · Pier Luigi Zinzani, Alessandro Broccoli, et al. · Journal of Clinical Oncology · 153
PDF
Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients
2011 · Pier Luigi Zinzani, Luigi Rigacci, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 125
Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
2011 · Pier Luigi Zinzani, Cinzia Pellegrini, et al. · Clinical Lymphoma Myeloma & Leukemia · 117
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial
2017 · Pier Luigi Zinzani, Cinzia Pellegrini, et al. · Blood · 105
PDF
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study
2016 · Claudio Agostinelli, Andrea Gallamini, et al. · The Lancet Haematology · 77
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials
2013 · P. L. Zinzani, S. Viviani, et al. · Haematologica · 73
PDF
Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients
2010 · Pier Luigi Zinzani, Giuseppe Rossi, et al. · Clinical Cancer Research · 68
PDF
Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma
2010 · Pier Luigi Zinzani, Letizia Gandolfi, et al. · Cancer · 64
Hairy cell leukemia: Evaluation of the long‐term outcome in 121 patients
2010 · Pier Luigi Zinzani, Cinzia Pellegrini, et al. · Cancer · 59
PDF
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified
2011 · Pier Luigi zinzani, Cinzia Pellegrini, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 57
Weight status and body image perception in Italian children
2007 · E. Gualdi‐Russo, A. Albertini, et al. · Journal of Human Nutrition and Dietetics · 54
Rheumatoid Arthritis and Cardiovascular Risk: Retrospective Matched-Cohort Analysis Based on the RECORD Study of the Italian Society for Rheumatology
2021 · Lisa Argnani, Anna Zanetti, et al. · Frontiers in Medicine · 52
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
2019 · A. Broccoli, L. Argnani, et al. · Blood Cancer Journal · 49
PDF
Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
2017 · Alessandro Broccoli, Lisa Argnani, et al. · Cancer Treatment Reviews · 46
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
2016 · Cinzia Pellegrini, Anna Dodero, et al. · Journal of Hematology & Oncology · 43
PDF
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B‐cell lymphoma: experience on 74 patients
2014 · Pier Luigi Zinzani, Alessandro Broccoli, et al. · Hematological Oncology · 42
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
2021 · Chiara Tarantelli, Lisa Argnani, et al. · Cancers · 39
PDF
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
2022 · Juan Pablo Alderuccio, Luca Arcaini, et al. · Blood Advances · 37
PDF
Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
2017 · Lisa Argnani, Alessandro Broccoli, et al. · Cancer Treatment Reviews · 36
Extranodal marginal zone B‐cell lymphoma of the lung: experience with fludarabine and mitoxantrone‐containing regimens
2012 · Pier Luigi Zinzani, Cinzia Pellegrini, et al. · Hematological Oncology · 36
Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience
2021 · Beatrice Casadei, Lisa Argnani, et al. · Cancers · 35
PDF
Primary Bone Lymphoma: Evaluation of Chemoimmunotherapy as Front-line Treatment in 21 Patients
2011 · Cinzia Pellegrini, Letizia Gandolfi, et al. · Clinical Lymphoma Myeloma & Leukemia · 34
Non-Hodgkin Lymphomas Presenting as Soft Tissue Masses: A Single Center Experience and Meta-Analysis of the Published Series
2012 · Enrico Derenzini, Beatrice Casadei, et al. · Clinical Lymphoma Myeloma & Leukemia · 33
Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor
2015 · Letizia Gandolfi, Sarah Adamo, et al. · Journal of the National Comprehensive Cancer Network · 31
Works count: 245
Citation count: 2,862
H-index: 28
I10-index: 73
Year
Topic
Type